| Name | Title | Contact Details |
|---|---|---|
Jinhee Chang |
Intellectual Property Counsel | Profile |
Fred Medick |
General Counsel | Profile |
Aviva Gilbert |
Assistant General Counsel, Senior | Profile |
Yan Qi |
Director and Assistant General Counsel, Platforms | Profile |
Sarah Tully |
Director and Assistant General Counsel | Profile |
What unites us at Rentschler Biopharma, is the passion for what we do. As a full-service CDMO we are your outsourcing partner for the bioprocess development, cGMP manufacturing and aseptic filling of biopharmaceuticals as well as for the elaboration of approval strategies for your products. Thanks to our many years of experience, the quality of our associated consulting activities, and our expertise in finding solutions, we are among the top suppliers in our field. Founded in 1927, Rentschler is a family owned and independent company. Our company structure guarantees rapid decision-making and efficient, smooth-running processes, and consequently keeping project timelines. Already in the early beginnings of biotechnology, Rentschler has built up a reputation with the development of different Interferon products (Fiblaferon, Polyferon). Nowadays, our attention is firmly focused on your products. For the success of your project we can refer to our experience in various molecules like antibodies, fusion proteins or enzymes. Thanks to our focus on innovations, we are always on the cutting edge of technologies.
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
We are harnessing the power of the immune system to target some of the most challenging solid tumor malignancies.
Takeda Oncology,, is a biopharmaceutical company based in Cambridge, Massachusetts.
Foresite Labs incubates companies that will address some of our greatest unmet medical needs. Their experienced team of scientists, engineers, and operators believes that the tools of data science, when applied with scientific rigor, will greatly accelerate scientific discovery and the development of new products and services that benefit patients. Through its incubation platform, Foresite Labs is dismantling the barriers faced by visionary entrepreneurs and their companies as they seek to re-invent healthcare. Foresite Labs Values Truth over progression: We follow the science, pursuing ideas that are grounded in data and abandoning them when not supported by the evidence. Take good risks: Our culture values informed risk-taking: good decisions are celebrated even when they result in bad outcomes. Everyone feels safe to contribute ideas and to learn from failure. Single accountable person: The project team lead is accountable for all decisions and for maintaining transparency and information flow within the team; we trust the project teams. The Review Committee unlocks capital and sets directions. Simplicity and Focus: Companies die from indigestion, not starvation (Bill Hewlett) We will focus on a few ideas aggressively and minimize all other distractions. Everyone will have a few key goals that have measurable outcomes. Respect and Community: Our employees are our greatest asset; everyone invests in creating an environment of collaboration and respect. We support their careers and career development whether they stay, go to a Labs company, or end up somewhere else.